Alton B. Kremer is VP & Clinical Research at PROGENICS PHARMACEUTICALS INC (PGNX). They have made 1 open-market trade across 1 company since 2006, most recently 2008-04-01.
CIK 0001327416
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PGNX | 28,171 | $116K |
Shares reported on the most recent Form 4, priced at the 2008-04-03 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.